Research ArticleCancer

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

See allHide authors and affiliations

Science Translational Medicine  18 Nov 2015:
Vol. 7, Issue 314, pp. 314ra185
DOI: 10.1126/scitranslmed.aac5272

Log in to view full text

Log in through your institution

Log in through your institution

Navigate This Article